Suppression of Autoimmune Rheumatoid Arthritis with Hybrid Nanoparticles That Induce B and T Cell Tolerance to Self-Antigen

• Published in: ACS nano 2022-12, Vol.16 (12), p.20206-20221
• Main Authors: Brzezicka, Katarzyna A., Arlian, Britni M., Wang, Shengyang, Olmer, Merissa, Lotz, Martin, Paulson, James C.
• Format: Article
• Language: English
• Subjects: Animals; Arthritis, Rheumatoid - drug therapy; Autoantigens; Autoimmune Diseases; Immune Tolerance; Lipids; Mice; Nanoparticles; Ovalbumin; Polylactic Acid-Polyglycolic Acid Copolymer
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.2c05643

Autoimmune diseases affect over 4% of the world’s population. Treatments are generally palliative or use broad spectrum immunosuppressants to reduce symptoms and disease progression. In some diseases, antibodies generated to a single autoantigen are the major cause of pathogenic inflammation, suggesting that treatments to induce tolerance to the autoantigen could be therapeutic. Here we report the development of hybrid nanoparticles (NPs) that induce tolerance in both T cells and B cells. The NPs comprise a lipid monolayer encapsulating a PLGA core loaded with rapamycin that promotes development of regulatory T cells (Tregs). The lipid monolayer displays the protein antigen and a ligand of the B cell inhibitory co-receptor CD22 (CD22L) that act together to suppress activation of B cells recognizing the antigen. We demonstrate that the hybrid NPs decorated with ovalbumin (OVA) elicit tolerance to OVA in naı̈ve mice, as judged by low OVA-specific antibody titers after the challenge. In the K/BxN mouse model of rheumatoid arthritis caused by B and T cell-dependent responses to the self-antigen glucose-6-phosphate-isomerase (GPI), we show that GPI hybrid NPs delay development of disease, with some treated mice remaining arthritis-free for 300 days. We provide evidence that the mechanism of rheumatoid arthritis suppression involves induction of B cell tolerance, as measured by low anti-GPI antibodies and decreased plasma cell populations, and T cell tolerance, as measured by increased Tregs. The results show the potential of this versatile NP platform for inducing immune tolerance to a self-antigen and suppressing autoimmune disease.